Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ReposiTrak (TRAK) Cash & Equivalents (2016 - 2025)

ReposiTrak has reported Cash & Equivalents over the past 16 years, most recently at $28.7 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $28.7 million for Q4 2025, up 2.37% from a year ago — trailing twelve months through Dec 2025 was $28.7 million (up 2.37% YoY), and the annual figure for FY2025 was $28.6 million, up 13.58%.
  • Cash & Equivalents for Q4 2025 was $28.7 million at ReposiTrak, roughly flat from $28.8 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TRAK hit a ceiling of $28.8 million in Q3 2025 and a floor of $20.4 million in Q3 2021.
  • Median Cash & Equivalents over the past 5 years was $23.8 million (2023), compared with a mean of $24.3 million.
  • Biggest five-year swings in Cash & Equivalents: grew 29.59% in 2021 and later dropped 10.84% in 2022.
  • ReposiTrak's Cash & Equivalents stood at $21.7 million in 2021, then dropped by 1.42% to $21.4 million in 2022, then rose by 8.66% to $23.3 million in 2023, then grew by 20.59% to $28.0 million in 2024, then rose by 2.37% to $28.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $28.7 million (Q4 2025), $28.8 million (Q3 2025), and $28.6 million (Q2 2025) per Business Quant data.